Research advances of corneal collagen cross-linking in the treatment of corneal diseases

Authors: Jia Guizhen,  Cheng Mengya,  Wang Linnong

DOI: 10.3760/cma.j.issn.2095-0160.2020.03.016
Published 2020-03-10
Cite as Chin J Exp Ophthalmol, 2020,38(03): 245-249.

Abstract                              [View PDF] [Read Full Text]

Corneal collagen cross-linking (CXL) has been proved to be a very safe and effective technique to halt the progression of many cornea diseases, such as ectasia disease, infectious keratitis and ametropia.CXL techniques include conventional CXL, accelerated CXL, transepithelial CXL and photochemical CXL.CXL can prevent the progression of dilated keratopathy, postpone or avoid corneal transplant surgery, and has an auxiliary function in the treatment of bullous keratopathy, infectious keratitis except herpes virus infection, and ametropia.CXL is not effective for patients with ocular herpes virus infection and patients with thin cornea and may even worsen the development of the disease.This review summarized the advantages and disadvantages of common CXL techniques, indications, contraindications, and complications, which may help enhancing the clinical application of CXL and reducing its complications.

Key words:

Corneal collagen cross-linking; Ectasia disease; Infectious Keratitis; Ametropia

Contributor Information

Jia Guizhen
Department of Ophthalmology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China (is working at Department of Ophthalmology, Childern’s Hospital of Nanjing Medical University, Nanjing 210008, China)
Cheng Mengya
Wang Linnong
(Read 36 times, 1 visits today)
Updated: December 27, 2022 — 7:47 am